Clover and Dynavax Announce Commercial Supply Agreement of Dynavax’s CpG 1018 Adjuvant for Clover’s COVID-19 Vaccine Candidate

CHENGDU, China, and EMERYVILLE, Calif.: CHENGDU, China, and EMERYVILLE, Calif., June 30, 2021 /PRNewswire/ -- Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates to address the world's most life-threatening diseases and public health threats, and Dynavax Technologies Corporation (Dynavax, Nasdaq: DVAX), a biopharmaceutical...

Click to view original post